| abstract |
The present disclosure provides methods, uses and kits for treating cancer in an individual. The method comprises a PD-1 axis binding antagonist (such as an anti-PD-1 antibody or an anti-PD-L1 antibody) and an RNA vaccine (eg, a cancer-specific somatic cell mutation present in a tumor specimen obtained from an individual) in an individual. Includes administration of an individualized cancer vaccine (individualized cancer vaccine) comprising one or more polynucleotides encoding one or more neoepitope resulting from. RNA molecule (eg, a personalized RNA cancer vaccine containing one or more polynucleotides encoding one or more neoepitogens resulting from cancer-specific somatic cell mutations present in tumor specimens obtained from an individual) Alongside, DNA molecules and methods useful for the production or use of RNA vaccines are further provided herein. [Selection diagram] Fig. 1 |